Vaccine Development

Canarypoxvirus-p53 vaccine elicits p53-specific immune response in colorectal cancer patients

Published in Vaccine Weekly, July 24th, 2002

by Maria G. Essig, MS, ELS, senior medical writer - A recombinant canarypoxvirus (ALVAC) expressing human p53 antigen stimulated a specific immune response in patients with advanced colorectal cancer, in a phase I/II study from the Netherlands.

Many types of tumor cells express the p53 antigen, which can elicit a T-cell-mediated immune response. Sjoerd H. van der Burg and colleagues at the Leiden University Medical Center in the Netherlands performed a phase I/II escalation study to determine the effect of a p53 vaccine in patients with colorectal cancer.

The investigators inoculated 15 patients who had advanced colorectal cancer with a recombinant...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-07-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry